Rare metabolic disorders that disrupt triglyceride breakdown remain a significant unmet need in cardiometabolic care. Among these, familial lipoprotein lipase deficiency — commonly referred to as LPL disease — stands out as a genetic condition with life-threatening complications and a growing pipeline of investigational therapies. According to DelveInsight's report on the topic, the disorder ari..